*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
IDEAYA Biosciences, with its market cap standing robustly at approximately $2.13 billion, is poised for its upcoming earnings announcement on August 12, 2025, amid a backdrop of strategic silence. The company's EPS estimate is set at $0.00, aligning with the whisper number, which suggests that analysts and investors are not anticipating surprises in profitability this quarter. Revenue is projected at $4.19 million, a figure that will be closely scrutinized given the lack of recent news or updates from the company. This absence of new information may indicate a period of strategic consolidation or internal focus, as IDEAYA continues to navigate the competitive landscape of biosciences. Investors will be keen to see if the company can maintain its market position and leverage its substantial market cap to drive future growth, despite the current expectation of flat earnings.
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
Website: https://www.ideayabio.com
Average Sentiment Score:
Overall Sentiment: